P53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 7, 2000, Pages 849-854

  Yair, Daniel ^a   Ben Baruch, Gilad ^b   Chetrit, Angela ^b   Friedman, Tal ^a   Yechezkel, Galit Hirsh ^b   Gotlieb, Walter H ^b   Fishman, Amiram ^c   Belter, Uzi ^d   Bar Am, Amiram ^e   Friedman, Eitan ^a  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d Sharre Tseddek Medical Centre   (Israel)

^e LIS MATERNITY HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; GUANINE; NUCLEOTIDE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CLINICAL FEATURE; DEMOGRAPHY; DNA DETERMINATION; DNA POLYMORPHISM; EPITHELIUM CELL; ETHNOLOGY; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRON; ISRAEL; JEW; MAJOR CLINICAL STUDY; NUCLEOTIDE REPEAT; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; BRCA2 PROTEIN; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, BRCA1; GENES, P53; GENOTYPE; HUMANS; ISRAEL; JEWS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0034046401     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb11082.x     Document Type: Article

References (34)

1. Miki Y, Swensen J, Shattuck-Eidens et al. A strong candidate for the breast and ovarian cancer susceptibility gene. Science 1994; 266: 66–71.
2. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13 q12–q13. Science 1994; 265: 2088–2090.
3. Modan B, Gak E, Sade-Bruchim RB et al. High frequency of BRCA1 185 delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA 1996; 276: 1823–1825.
4. Beller U, Halle D, Catane R, Kaufman B, Hornreich G, Levy-Lahad E. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997; 67: 123–126.
5. Abeliovich D, Kaduri L, Lerer I et al. The founder mutation 185 delAG and 5382 insC in BRCA1 and 6174 delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer among Ashkenazi women. Am J Hum Genet 1997; 60: 505–514.
6. Lalloo F, Cochrane S, Blumen B et al. An evaluation of common breast cancer gene mutation in a population of Ashkenazi Jews. J Med Genet 1998; 35: 10–12.
7. Straewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401–1408.
8. Ealy B. BRCA genes: bookmaking, fortunetelling and medical care. N Engl J Med 1997; 336: 1448–1449.
9. Phelan CM, Rebbeck TR, Weber BL et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeats (VNTR) locus. Nature Genet 1996; 12: 309–311.
10. Zhang H, Somasundaram K, Peng Y et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998; 16: 1713–1721.
11. Ouchi T, Monterio AM, August A, Aaronson SA, Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 1998; 95:2302–2306.
12. Chai YL, Cui J, Shyam E, Reddy P, Rao VN. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21 WAF1/CIP1 promoter. Oncogene 1999; 18: 263–268.
13. Gretarsdottir S, Thorlacius S, Valgardsdottir R et al. BRCA2 and p53 mutation in primary breast cancer in relation to genetic instability. Cancer Res 1998; 58: 859–862.
14. Sobol H, Stoppa-Lyonnet D, Bressac-Depaillerets B et al. BRCA1-p53 relationship in hereditary breast cancer. Int J Oncol 1997; 10: 349–353.
15. Hakem R, Pompa JLD, Sirard C et al. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009–1023.
16. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutation of breast cancer susceptibility gene homologous in mice: lethal phenotypes of BRCA1, BRCA2, BRCA1/BRCA2, BRCA1/p53 nullizygous embryos. Genes Dev 1997; 11: 1242–1252.
17. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of BRCA1 early embryonic lethality by p53 or p21 nulls mutation. Nature Genet 1997; 16: 298–302.
18. Somasundaram K, Zhang H, Zeng YX et al. Arrest of cell cycle by the tumor-suppressor BRCA1 requires the cdk-inhibitor p21 WAF1/CiP. Nature 1997; 389: 187–190.
19. Runnebaum IB, Tong XW, Konig R et al. P53 based blood test for p53 pin3 and risk for sporadic ovarian cancer. Lancet 1995; 345: 994–995.
20. Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993; 8: 1703–1705.
21. McDaniel T, Carbone D, Takahashi T et al. The Mspl polymorphism in intron 6 of p53 detected by digestion of PCR products. Nucleic Acid Res 1991; 19: 4796.
22. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 1994; 9: 3021–3024.
23. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 1997; 43: 24–29.
24. Campbell LIG, Eccles DM, Dunn B, Davis M, Leake V. TP53 polymorphism in ovarian and breast-cancer. Lancet 1996; 347: 393–394.
25. Lancaster JM, Brownlee HA, Weisman RW, Taylor J. P53 polymorphism in ovarian and bladder cancer. Lancet 1995; 346: 182.
26. Skilling JS, Powills RN, Lager DJ, Anderson B, Sorosky J, Buller RE. P53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol Oncol 1996; 61: 180–188.
27. Peller S, Kopilova Y, Slutzki A, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 1995; 14: 983–990.
28. Avigad S, Barel D, Blau O et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogenes 1997; 14: 1541–1545.
29. Mavridou D, Gornall R, Campbell IG, Eccles DM. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer 1998; 77: 676–678.
30. Wan M, Cofer KF, Dubeau L. WAF1/CIP1 structural abnormalities do not contribute to cell cycles deregulation in ovarian cancer. Br J Cancer 1996; 73: 1398–1400.
31. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Bevilacqua G. Absence of somatic mutation in the coding region of the WAF1/CIP1 gene in human breast, lung, and ovarian carcinoma: A polymorphism at codon 31. Int J Oncol 1995; 6: 187–189.
32. Lukas J, Groshen S, Saffari B et al. WAF1/CIP1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997; 150: 167–175.
33. CIP/WAF1are not correlated with TP53 status in sporadic ovarian tumorous. Eur J Cancer 1996; 32: 2360–2363.
34. Elbendary AA, Cirisano FD, Evans AC et al. Relationship between p21 expression and mutation of p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996; 2: 1571–1575.